公开(公告)号：EP1234033B1

公开(公告)日：2011-12-28

申请号：EP00980829.6

申请日：2000-11-28

申请人： ZymoGenetics, Inc.

发明人： WEST, James, W.

IPC分类号： C12N15/12 ,  C07K14/50 ,  C12N15/18 ,  C12N15/62 ,  A61K38/18

CPC分类号： A61K38/1825 ,  A61K47/642

摘要： Fibroblast growth factor-18 (FGF-18) binds with FGF receptors-2 and -3. Compositions comprising an FGF-18 component can be used to target cells that express these receptors. Suitable targets include tumor cells that express constitutively activated forms of FGF receptors-2 and -3.

公开(公告)号：EP1137773A2

公开(公告)日：2001-10-04

申请号：EP99966032.7

申请日：1999-12-07

申请人： ZymoGenetics, Inc.

发明人： GAO, Zeren ,  HART, Charles, E. ,  PIDDINGTON, Christopher, S. ,  SHEPPARD, Paul, O. ,  SHOEMAKER, Kimberly, E. ,  GILBERTSON, Debra, G. ,  WEST, James, W.

IPC分类号： C12N15/12 ,  C12N15/11 ,  C12N5/10 ,  C12N15/62 ,  C07K14/52 ,  C07K16/22 ,  G01N33/68 ,  C12Q1/68 ,  A61K38/18

CPC分类号： C07K14/475 ,  A61K38/00 ,  C07K14/52

摘要： Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprises an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.

公开(公告)号：EP1303602B1

公开(公告)日：2006-12-27

申请号：EP01926604.8

申请日：2001-04-03

申请人： ZymoGenetics, Inc.

发明人： SPRECHER, Cindy, A. ,  NOVAK, Julia, E. ,  WEST, James, W. ,  PRESNELL, Scott, R. ,  HOLLY, Richard, D. ,  NELSON, Andrew, J.

IPC分类号： C12N15/12 ,  C12N15/62 ,  C12N5/10 ,  C07K14/715 ,  C07K16/28 ,  A61K38/19

CPC分类号： C07K16/2866 ,  A61K38/00 ,  C07K14/7155 ,  C07K2317/73 ,  C07K2319/00

摘要： Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonist, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

公开(公告)号：EP2044118A2

公开(公告)日：2009-04-08

申请号：EP07798524.0

申请日：2007-06-13

申请人： Zymogenetics, Inc.

发明人： LEWIS, Katherine, E. ,  PRESNELL, Scott R. ,  WEST, James, W. ,  MABRY, Robert, ,  MEENGS, Brent

IPC分类号： C07K16/24 ,  C12N15/13 ,  A61K39/395 ,  A61P37/06

CPC分类号： C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

公开(公告)号：EP1137773B1

公开(公告)日：2008-08-13

申请号：EP99966032.7

申请日：1999-12-07

申请人： ZymoGenetics, Inc.

发明人： GAO, Zeren ,  HART, Charles, E. ,  PIDDINGTON, Christopher, S. ,  SHEPPARD, Paul, O. ,  SHOEMAKER, Kimberly, E. ,  GILBERTSON, Debra, G. ,  WEST, James, W.

IPC分类号： C12N15/12 ,  C12N15/11 ,  C12N5/10 ,  C12N15/62 ,  C07K14/52 ,  C07K16/22 ,  G01N33/68 ,  C12Q1/68 ,  A61K38/18

CPC分类号： C07K14/475 ,  A61K38/00 ,  C07K14/52

公开(公告)号：EP1451322B1

公开(公告)日：2009-09-30

申请号：EP02773925.9

申请日：2002-10-28

申请人： ZymoGenetics, Inc.

发明人： PRESNELL, Scott, R. ,  WEST, James, W. ,  NOVAK, Julia, E.

IPC分类号： C12N15/12 ,  C12N5/10 ,  C12N15/63 ,  C12P21/02 ,  C07K14/47

CPC分类号： C07K14/54 ,  A61K38/00 ,  C07K14/7155 ,  C07K2319/00 ,  C12N2799/026

摘要： The polypeptides, and the polynucleotides encoding for them, described herein are IL-21 antagonists that bind with specificity and exhibit an EC50 that is not detectable in receptor binding studies. These molecules have mutations in the D helix of the IL-21 molecule, and can be used to inhibit the activity of IL-21 with its cognate receptor.

公开(公告)号：EP2007806A2

公开(公告)日：2008-12-31

申请号：EP07760661.4

申请日：2007-04-13

申请人： ZymoGenetics, Inc.

发明人： WEST, James, W.

IPC分类号： C07K14/705

CPC分类号： C07K14/70532 ,  C07K14/00 ,  C07K14/47 ,  C07K2319/00 ,  C12N15/62

摘要： The present invention relates to a method of preparing a tetrameric protein comprising culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a vasodialator-stimulated phosphoprotein (VASP) domain and a heterologous protein. In one embodiment, the heterologous protein is a membrane protein, the portion of the heterologous protein that included in the fusion protein is the extracellular domain of that protein, and the resulting fusion protein is soluble. The method can be used to produced homo- and hetero-tetrameric proteins. The present invention also encompasses DNA molecules, expression vectors, and host cells used in the present method and fusion proteins produced by the present method.

公开(公告)号：EP1891107A2

公开(公告)日：2008-02-27

申请号：EP06759739.3

申请日：2006-05-12

申请人： ZymoGenetics, Inc.

发明人： LEVIN, Steven, D. ,  BILSBOROUGH, Janine ,  WEST, James, W. ,  BRANDT, Cameron ,  RAMSDELL, Frederick, J. ,  HOWARD, Edward, D. ,  CHADWICK, Eric, M. ,  GAO, Zeren

IPC分类号： C07K14/705 ,  C07K16/28 ,  C12N15/62 ,  A61K38/17

CPC分类号： C07K16/2827 ,  A61K38/00 ,  A61K2039/507 ,  C07K14/47 ,  C07K14/70532 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C12Q1/66 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/70532

摘要： The present invention provides a newly identified B7 receptor, zB7Rl that functions as lymphocyte inhibitory receptor, which is a PD-I -like molecule and is expressed on T cells. The present invention also provides the discovery of zB7Rl's ability to bind to CD155. Methods and compositions for modulating zB7Rl -mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

公开(公告)号：EP1891107B1

公开(公告)日：2011-07-06

申请号：EP06759739.3

申请日：2006-05-12

申请人： ZymoGenetics, Inc.

发明人： LEVIN, Steven, D. ,  BILSBOROUGH, Janine ,  WEST, James, W. ,  BRANDT, Cameron ,  RAMSDELL, Frederick, J. ,  HOWARD, Edward, D. ,  CHADWICK, Eric, M. ,  GAO, Zeren

IPC分类号： C07K14/705 ,  C07K16/28 ,  C12N15/62 ,  A61K38/17

CPC分类号： C07K16/2827 ,  A61K38/00 ,  A61K2039/507 ,  C07K14/47 ,  C07K14/70532 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C12Q1/66 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/70532

摘要： The present invention provides a newly identified B7 receptor, zB7Rl that functions as lymphocyte inhibitory receptor, which is a PD-I -like molecule and is expressed on T cells. The present invention also provides the discovery of zB7Rl's ability to bind to CD155. Methods and compositions for modulating zB7Rl -mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

摘要翻译： 提供了zB7R1的拮抗剂，其中拮抗剂抑制zB7R1介导的信号传导，包括：（i）抑制zB7R1与其反受体之间的相互作用的阻断剂; （ii）针对zB7R1多核苷酸的反义寡核苷酸或抑制性RNA序列，其中所述zB7R1多核苷酸包含选自SEQ ID NO：1和SEQ ID NO：5的核苷酸序列，或编码多肽的核苷酸序列 SEQ ID NO：2，SEQ ID NO：3，SEQ ID NO：6和SEQ ID NO：7的序列; （iii）针对zB7R1反受体的核酸序列的反义寡核苷酸或抑制性RNA序列; （iv）可溶性CD155多肽或融合蛋白，其中所述可溶性CD155多肽或融合蛋白具有修饰的氨基酸序列，因此不能激活zBTR1介导的信号传导，并且其中所述可溶性CD155多肽或融合蛋白抑制zB7R1 和CD155; 或（v）zB7R1与CD155之间相互作用的小分子抑制剂。 还提供了可溶性zB7R1多肽，其包含与SEQ ID NO：2的氨基酸残基16-140或SEQ ID NO：6的氨基酸残基27-208具有至少95％序列同一性的氨基酸残基序列，其中所述 可溶性多肽刺激B7R1介导的信号转导。

公开(公告)号：EP2283039A1

公开(公告)日：2011-02-16

申请号：EP08771114.9

申请日：2008-06-13

申请人： ZymoGenetics, Inc.

发明人： WEST, James, W.

IPC分类号： C07K16/00

CPC分类号： C07K16/00 ,  C07K2317/55 ,  C07K2317/622

摘要： In various embodiments, the present invention provides methods of converting a Fab molecule to a scFv molecule. The methods include amplifying the polynucleotide sequence of the variable light and variable heavy regions of the Fab molecule from the framework 1 to framework 4 sequences; adding one or more restriction endonuclease sites to the amino or carboxyl terminal of the amplified variable region sequence by PCR or ligation; adding one or more linker sequences to the amino or carboxyl terminal of the amplified variable region sequence by PCR or ligation. Additionally, in various embodiments the variable light chain sequence is either amino terminal or carboxyl terminal to the variable heavy chain sequence.